Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.

BMC cancer - 31 Mar 2023

Xie Jianjiang, Yao Weishen, Chen Lingxiu, Zhu Wenjun, Liu Qiang, Geng Geng, Fang Jing, Zhao Yang, Xiao Li, Huang Zhenhua, Zhao Jing

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) has been becoming a novel convenient and noninvasive method for dynamically monitoring landscape of genomic information to guild personalized cancer treatment. In this study we comprehensively evaluated the additional value of plasma ctDNA to routine tissue next generation sequencing (NGS) of therapeutically targetable mutations in lung cancers. METHODS: The tumor tissues...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 37004022
DOI: 10.1186/s12885-023-10674-z
PMCID: PMC10063947

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.PMID 37004022Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.Semantic proximity Read ↗

Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next-Generation Sequencing With Insufficient Tumor Samples.Semantic proximity Read ↗

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patientsSemantic proximity Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patientsSemantic proximity Read ↗

Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients.Semantic proximity Read ↗

Plasma cell-free DNA methylation combined with tumor mutation detection in prognostic prediction of patients with non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.Semantic proximity Read ↗

Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.